Opus Genetics (IRD) Total Debt (2021 - 2026)
Opus Genetics' (IRD) quarterly Total Debt came in at $1.2 million in Q1 2026, up 6.11% on a QoQ basis from $1.1 million in Q4 2025.
Opus Genetics (IRD) Total Debt (2021 - 2026) Analysis & Trends
Opus Genetics (IRD) has 4 years of Total Debt data on file, last reported at $1.2 million in Q1 2026.
- On a quarterly basis, Total Debt changed N/A year-over-year to $1.2 million in Q1 2026; TTM through Mar 2026 was $1.2 million, a N/A change from a year earlier, with the FY2025 full-year figure at $1.1 million, changed N/A from the prior year.
- Total Debt for Q1 2026 stood at $1.2 million, up from $1.1 million in the prior quarter.
- Over the last five years, Total Debt for IRD reached as high as $1.2 million in Q1 2026 and fell as low as $215000.0 in Q1 2022.
- Historically, Total Debt has averaged $922000.0 across 3 years, with a median of $1.1 million in 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.96 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 959.06 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.99 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Opus Genetics | 3.27 Mn | -56.73 Mn | - | 1.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.20 Mn |
| Dec 31, 2025 | 1.13 Mn |
| Sep 30, 2025 | 1.07 Mn |
| Jun 30, 2025 | 1.00 Mn |
| Mar 31, 2022 | 215,000.00 |
| Dec 31, 2021 | 538,000.00 |